FibroGen Stock News

FibroGen press release (FGEN): Q4 GAAP EPS of -$1.45 misses by $0.74.Revenue of $16.54M (-74.5% Y/Y) misses by $31.11M.

SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2021 and provided an update on the company’s recent developments.

FibroGen (FGEN) delivered earnings and revenue surprises of -113.24% and 62.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (NASDAQ:FGEN) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.63 (+1.6% Y/Y) and the consensus…

SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close. Fibr

SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST.

SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11

SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwrigh

During the last session, FibroGen Inc. (NASDAQ:FGEN)s traded shares were 7.55 million, with the beta value of the company hitting 0.88. At the end of the trading day, the stocks price was $14.77, reflecting an intraday gain of 5.50% or $0.77. The 52-week high for the FGEN share is $57.21, that puts it down -287.34 A Quick Glance At FibroGen Inc. (NASDAQ: FGEN) Stock: It Is up 33.11% From Its 52-Week Low; YTD, It Is Down -60.18 Percent Read More »

Wall Street analysts expect that FibroGen, Inc. (NASDAQ:FGEN) will announce earnings of ($0.68) per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for FibroGens earnings. The lowest EPS estimate is ($0.76) and the highest is ($0.59). FibroGen posted earnings per share of ($0.64) during the same quarter last year, []

This move is a reversal from the hour prior, which saw price move up. The post Fibrogen Inc (FGEN): Price Now Near $14.85; Daily Chart Shows An Uptrend on 50 Day Basis appeared first on ETF Daily News .

Bank of America Corp DE lessened its holdings in shares of FibroGen, Inc. (NASDAQ:FGEN) by 60.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,546 shares of the biopharmaceutical companys stock after selling 163,081 shares during the period. Bank []

FibroGen Inc. (NASDAQ:FGEN) shares, rose in value on Friday, 11/26/21, with the stock price down by -5.66% to the previous days close as strong demand from buyers drove the stock to $12.17. Actively observing the price movement in the last trading, the stock closed the session at $12.90, falling within a range of $12.00 and FibroGen Inc. (NASDAQ: FGEN) Stock Price Forecast: $100 Read More »

UBS Asset Management Americas Inc. reduced its position in shares of FibroGen, Inc. (NASDAQ:FGEN) by 13.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 82,249 shares of the biopharmaceutical companys stock after selling 12,539 shares during the period. UBS Asset []